Skip to main
SNTI

SNTI Stock Forecast & Price Target

SNTI Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Senti Biosciences is actively pursuing its goal to develop innovative cell and gene therapies for patients with incurable diseases. In addition to promising data from their ongoing Phase 1 clinical trial for SENTI-202, the company has also seen positive results from its gene circuit platform, particularly with Donor X phenotype. While financing remains a risk, our financial analysis suggests the potential for significant future revenues with an aggressive expansion strategy.

Bears say

Senti Biosciences is a biotech company with a promising product in SENTI-202, but they face several challenges and risks that may hinder their potential for success. With regulatory unknowns and potential toxicities, as well as financial uncertainties, the company's future value and success depend heavily on the launch and adoption of their product in the market. Additionally, competition and manufacturing challenges add further risks to their outlook.

SNTI has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Senti Biosciences Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Senti Biosciences Holdings Inc (SNTI) Forecast

Analysts have given SNTI a Strong Buy based on their latest research and market trends.

According to 4 analysts, SNTI has a Strong Buy consensus rating as of May 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Senti Biosciences Holdings Inc (SNTI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.